Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers

NCT05227768 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: VV116 25mg Group
DRUG: VV116 200mg Group
DRUG: VV116 400mg Group
DRUG: VV116 800mg Group
DRUG: VV116 1200mg Group

Sponsor

Vigonvita Life Sciences